替格瑞洛与氯吡格雷用于中国急性冠状动脉综合征患者的药效学分析 - Suppr | 超能文献

相似文献

1

Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.替格瑞洛与氯吡格雷用于中国急性冠状动脉综合征患者的药效学分析

Int J Cardiol. 2015 Dec 15;201:545-6. doi: 10.1016/j.ijcard.2015.06.030. Epub 2015 Jun 19.

2

Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.用于治疗急性冠状动脉综合征的口服抗血小板药物的进展：氯吡格雷、普拉格雷和替格瑞洛。

J Pharm Pract. 2016 Jun;29(3):239-49. doi: 10.1177/0897190014568383. Epub 2015 Feb 8.

3

Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.替格瑞洛与氯吡格雷对接受择期经皮冠状动脉介入治疗的低危 ACS 且肌钙蛋白阴性患者的影响。

J Am Coll Cardiol. 2016 Feb 16;67(6):603-613. doi: 10.1016/j.jacc.2015.11.044.

4

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.替格瑞洛与氯吡格雷对高反应性血小板治疗的影响：ONSET/OFFSET 和 RESPOND 研究的联合分析。

Am Heart J. 2011 Jul;162(1):160-5. doi: 10.1016/j.ahj.2010.11.025. Epub 2011 Jun 12.

5

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.血小板功能检测指导氯吡格雷低反应者和高反应者治疗的未来。

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):999-1014. doi: 10.1586/erc.11.80.

6

Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.替格瑞洛治疗非ST段抬高型急性冠状动脉综合征的药代动力学和药效学

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):977-93. doi: 10.1517/17425255.2015.1037279. Epub 2015 Apr 16.

7

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.首个可逆性口服P2Y(12)受体拮抗剂替格瑞洛与氯吡格雷在急性冠脉综合征患者中的比较：血小板抑制和患者预后（PLATO）试验的原理、设计及基线特征

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

8

Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia.在心脏骤停后接受治疗性低温治疗的患者中，替格瑞洛优于氯吡格雷。

Can J Cardiol. 2014 Nov;30(11):1396-9. doi: 10.1016/j.cjca.2014.07.745. Epub 2014 Aug 15.

9

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.替格瑞洛：一种用于治疗急性冠脉综合征的 P2Y12 拮抗剂。

Expert Rev Clin Pharmacol. 2012 May;5(3):257-69. doi: 10.1586/ecp.12.17.

10

Cigarette smoking and clopidogrel interaction.吸烟与氯吡格雷相互作用。

Curr Cardiol Rep. 2013 May;15(5):361. doi: 10.1007/s11886-013-0361-7.

引用本文的文献

1

Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.替格瑞洛与氯吡格雷在因急性冠状动脉综合征行经皮冠状动脉介入治疗的重度肾功能不全患者中的比较。

J Interv Cardiol. 2022 Jul 31;2022:6476777. doi: 10.1155/2022/6476777. eCollection 2022.

2

Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome.急性冠状动脉综合征抗栓治疗的当前观点

Int J Gen Med. 2022 Mar 3;15:2397-2414. doi: 10.2147/IJGM.S289295. eCollection 2022.

3

Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.